SCTL vs. IMUX, ADAG, COYA, CTXR, ANVS, OPTN, RPTX, NVCT, INCR, and VTGN
Should you be buying Societal CDMO stock or one of its competitors? The main competitors of Societal CDMO include Immunic (IMUX), Adagene (ADAG), Coya Therapeutics (COYA), Citius Pharmaceuticals (CTXR), Annovis Bio (ANVS), OptiNose (OPTN), Repare Therapeutics (RPTX), Nuvectis Pharma (NVCT), InterCure (INCR), and Vistagen Therapeutics (VTGN). These companies are all part of the "pharmaceutical preparations" industry.
Societal CDMO (NASDAQ:SCTL) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.
In the previous week, Immunic had 3 more articles in the media than Societal CDMO. MarketBeat recorded 3 mentions for Immunic and 0 mentions for Societal CDMO. Immunic's average media sentiment score of 0.21 beat Societal CDMO's score of 0.00 indicating that Immunic is being referred to more favorably in the news media.
Societal CDMO has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500. Comparatively, Immunic has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500.
Societal CDMO presently has a consensus target price of $1.80, suggesting a potential upside of 63.64%. Immunic has a consensus target price of $8.50, suggesting a potential upside of 585.48%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than Societal CDMO.
Immunic received 86 more outperform votes than Societal CDMO when rated by MarketBeat users. However, 80.00% of users gave Societal CDMO an outperform vote while only 66.20% of users gave Immunic an outperform vote.
Societal CDMO has higher revenue and earnings than Immunic. Societal CDMO is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.
87.2% of Societal CDMO shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 7.6% of Societal CDMO shares are held by insiders. Comparatively, 2.7% of Immunic shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Immunic has a net margin of 0.00% compared to Societal CDMO's net margin of -14.03%. Societal CDMO's return on equity of -23.82% beat Immunic's return on equity.
Summary
Societal CDMO and Immunic tied by winning 8 of the 16 factors compared between the two stocks.
Get Societal CDMO News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Societal CDMO Competitors List
Related Companies and Tools
